Villejuif

The trials here

What the 34 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Metastatic breast cancer6 trials
• Ovarian cancer6 trials
• Triple-negative breast cancer6 trials
• Gastric and oesophageal cancer4 trials
• Cervical cancer3 trials
• Prostate cancer3 trials
• Endometrial cancer2 trials
• Follicular lymphoma2 trials
• Head and neck cancer2 trials
• Hodgkin lymphoma2 trials
• Kidney cancer2 trials
• and 8 more

Phase

• Phase 313 trials
• Phase 1/28 trials
• Phase 16 trials
• Phase 25 trials

Status

• Active, not recruiting17 trials
• Completed9 trials
• Recruiting5 trials
• Not yet recruiting2 trials
• Withdrawn1 trial

Lead sponsor

• AstraZeneca29 trials
• MedImmune LLC3 trials
• Alterome Therapeutics, Inc.1 trial
• Arcus Biosciences, Inc.1 trial

Running trials

• Recruiting

  A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  NCT07647328· Phase 3· AstraZeneca· Source

• Recruiting

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  NCT06542250· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

  NCT06533059· Phase 1· Alterome Therapeutics, Inc.· Source

• Recruiting

  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  NCT06137144· Phase 1/2· AstraZeneca· Source

• Recruiting

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· Phase 3· AstraZeneca· Source

  Contact: AstraZeneca Breast Cancer Study Locator Service

• Active, not recruiting

  Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

  NCT05771480· Phase 3· AstraZeneca· Source

• Recruiting

  Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

  NCT06005493· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  PASS of Paediatric Patients Initiating Selumetinib

  NCT05388370· AstraZeneca· Source

• Active, not recruiting

  A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

  NCT04639219· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

  NCT04538742· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

  NCT04556773· Phase 1· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

  NCT04550260· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  NCT04494425· Phase 3· AstraZeneca· Source

• Active, not recruiting

  COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

  NCT04068610· Phase 1/2· MedImmune LLC· Source

• Active, not recruiting

  Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

  NCT03997123· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

  NCT03530397· Phase 1· MedImmune LLC· Source

• Active, not recruiting

  To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

  NCT03330847· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Savolitinib vs. Sunitinib in MET-driven PRCC.

  NCT03091192· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

  NCT02734004· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

  NCT02264678· Phase 1· AstraZeneca· Source

• Active, not recruiting

  Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

  NCT01843374· Phase 2· MedImmune LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Recruiting

  Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

  NCT07181161· Phase 1/2· AstraZeneca· Source

• Completed

  A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

  NCT05329766· Phase 2· Arcus Biosciences, Inc.· Source

• Completed

  Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  NCT05008055· Phase 2· AstraZeneca· Source

• Completed

  Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

  NCT04532645· AstraZeneca· Source

• Completed

  First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

  NCT04504669· Phase 1· AstraZeneca· Source

• Completed

  AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02296125· Phase 3· AstraZeneca· Source

• Completed

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· Phase 3· AstraZeneca· Source

• Completed

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· Phase 3· AstraZeneca· Source

• Completed

  AZD9291 First Time In Patients Ascending Dose Study

  NCT01802632· Phase 1/2· AstraZeneca· Source

• Completed

  Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

  NCT01226316· Phase 1· AstraZeneca· Source